Action ATHA ATHIRA PHARMA, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Athira Pharma, Inc.

Actions

ATHA

US04746L1044

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 16/07/2024 		Varia. 5j. Varia. 1 janv.
3,36 USD 0,00 % Graphique intraday de Athira Pharma, Inc. -0,88 % +38,27 %
09/07 Mise à jour sectorielle : Les actions du secteur de la santé sont mitigées en fin d'après-midi MT
09/07 Mise à jour sectorielle : Soins de santé MT

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's disease
AQ
Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
GL
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
GL
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
GL
Glancy Prongay & Murray LLP and Labaton Keller Sucharow LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of the Publicly Traded Common Stock of Athira Pharma, Inc. - (NASDAQ: ATHA)
PR
Athira Pharma to Participate in Upcoming June Conferences
GL
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
GL
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
GL
Athira Pharma to Participate in Upcoming May Conferences
GL
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
GL
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's disease
AQ
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
GL
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
AQ
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
GL
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
GL
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
GL
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
GL
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
AQ
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
GL
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ATHA
  4. Actualités Athira Pharma, Inc.
  5. Communiqués